Sionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences
Sionna Therapeutics (SION) announced that management will participate in fireside chats at two upcoming investor conferences in November 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sionna Therapeutics (SION) announced that management will participate in fireside chats at two upcoming investor conferences in November 2026.
The Guggenheim Healthcare Innovation Conference chat is November 9 at 10:30 a.m. ET; the Stifel Healthcare Conference chat is November 10 at 8:40 a.m. ET. Live webcasts will be accessible through Sionna’s investor website, with replays available afterward.
Details
Market move: SION -4.13% vs previous close. November 2026 conference participation
On Nov 2, the day this news came out, the latest delayed price for SION is 4.13% below the previous close. Our momentum scanner has recorded 4 alerts for this stock so far that day. The latest delayed price is $3.71.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Terms
cystic fibrosis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to develop novel medicines for cystic fibrosis (CF), today announced that management will participate in fireside chats at the following upcoming investor events:
- Guggenheim's 3rd Annual Healthcare Innovation Conference fireside chat on Monday, November 9th, 2026, at 10:30 a.m. ET; and
- Stifel’s 2026 Healthcare Conference fireside chat on Tuesday, November 10th, 2026, at 8:40 a.m. ET
Live webcasts can be accessed in the ‘Investors’ section of Sionna’s website at https://investors.sionnatx.com. Replays will also be available following the events.
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking meaningful improvements in clinical outcomes and quality of life for people with CF. For more information about Sionna, visit www.sionnatx.com.
Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna’s Investor Relations website, in addition to following Sionna’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Investor & Media Contact
Juliet Labadorf
ir@sionnatx.com
media@sionnatx.com
